Αποτελέσματα Αναζήτησης
4 Ιαν 2023 · Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus’ protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle.
24 Ιουλ 2024 · A twice-yearly PrEP choice could overcome challenges with respect to adherence and persistence and result in substantial protection against HIV infection for women worldwide.
24 Ιουλ 2024 · The twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections, demonstrating 100% efficacy in Phase 3 trial data released by drugmaker Gilead and...
24 Ιουλ 2024 · Twice-yearly shots used to treat AIDS were 100 percent effective in preventing new infections in women, according to study results published Wednesday.
11 Δεκ 2023 · Cabotegravir is an intramuscular injection administered every 2 months for HIV PrEP; rapid detection of new HIV infection in people taking cabotegravir is an emerging concern. Lenacapavir given subcutaneously every 6 months is promising and currently in clinical trials for HIV PrEP.
23 Δεκ 2021 · The Food and Drug Administration has approved the first injectable medication for HIV prevention. Health advocates say it could be a game changer in protecting people against AIDS
24 Ιουν 2024 · MONDAY, June 24, 2024 -- Just two injections a year of a new HIV drug protected young women in Africa from infection with the sexually transmitted disease, new trial results show. In announcing the findings, Gilead Sciences Inc. said its HIV medication lenacapavir demonstrated 100% efficacy as a preventive treatment.
